ArticleNucleic acids research2026
Harnessing natural RNA triplex elements found in lncRNAs MALAT1 and NEAT1 for engineering of novel riboswitch platforms.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Synthetic riboswitches are efficient tools to render gene expression inducible by small molecules. Here, we present a novel riboswitch platform based on RNA triplexes stabilizing non-polyadenylated transcripts while still allowing translation of the respective messenger RNA. By incorporating a tetracycline aptamer, we rendered triplex formation dependent upon the presence of the ligand. The new riboswitch platform was able to induce gene expression up to 25-fold as a standalone switch. Combination of the triplex system with an aptazyme placed into the 5'-UTR achieved a 42-fold induction of gene expression. Further, we were able to exchange the triplex, the aptamer, the maturation platform cleaving off the poly-A tail of the switch platform, and the regulated transgene, demonstrating a high degree of modularity. The new riboswitch platform is designed to function independently of nuclear processes such as transcription and RNA processing, potentially expanding the application of these synthetic riboswitches to strictly cytoplasmic therapeutic RNA vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.